Can vascular, kidney, and metabolic dysfunction contribute to cognitive impairment alongside Alzheimer pathology?

In an 84-year-old man, cognitive impairment may reflect interacting neurodegenerative and systemic vascular processes rather than Alzheimer pathology alone. The overall claim is plausible with moderate confidence: vascular disease and diabetes-related metabolic dysfunction have the most direct support for impaired cerebral vascular regulation, while kidney dysfunction is a credible but less directly established contributor.

Clinical and cerebrovascular evidence

• Cerebral large- and small-vessel disease are associated with lower cerebral blood flow and cerebrovascular reactivity; a systematic review/meta-analysis of nine studies found substantial impairment versus controls.
• Type 2 diabetes is associated with altered—generally reduced—cerebral perfusion, impaired carbon-dioxide reactivity/dynamic autoregulation, faster cognitive decline, and increased dementia risk. In older adults with diabetes, worsening vasoreactivity over two years tracked functional decline.
• Kidney dysfunction, substantial eGFR decline, and incident albuminuria are associated with progression of white-matter hyperintensities, subcortical infarcts, and deep microbleeds. CKD, lower eGFR, and albuminuria are also associated with cognitive decline or dementia in longitudinal meta-analytic evidence, although these associations are heterogeneous and do not establish causality.

Alzheimer–vascular interaction

• Longitudinal autopsy evidence indicates that infarcts and other cerebrovascular injuries are associated with poorer cognition and dementia even after accounting for Alzheimer pathology.
• Amyloid-β and tau positivity are associated with faster cognitive decline, including in people with cerebrovascular disease. Alzheimer and vascular pathologies commonly coexist; vascular injury may lower the clinical threshold at which cognitive deficits become evident.

Mechanistic context

• Endothelial dysfunction, reduced nitric-oxide bioavailability, inflammation, blood–brain-barrier disruption, and increased arterial pulsatility can impair vasodilation, perfusion regulation, and microvascular integrity.
• Renal dysfunction may contribute through shared small-vessel disease, inflammation, vascular risk, and possible uremic toxicity, but direct evidence of reduced cerebrovascular reactivity remains inconsistent.

Bottom line

• Vascular disease and metabolic dysfunction can meaningfully add to cognitive impairment alongside Alzheimer pathology; kidney impairment is a plausible contributory pathway, particularly through cerebral small-vessel injury.